American Society of Hematology

Figure 3.

PFS by MRD levels at defined time points for patients randomly assigned to the FCR arm. MRD detectable or not at 3 months (A); cutoff levels of 10−3, 10−2, and 10−1 at 3 months (B); MRD detectable or not at 12 months (C); cutoff levels of 10−3, 10−2, and 10−1 at 12 months (D); MRD detectable or not at 24 months (E); cutoff levels of 10−3, 10−2, and 10−1 at 24 months (F); MRD detectable or not at 36 months (G); and cutoff levels of 10−3, 10−2, and 10−1 at 36 months (H).

PFS by MRD levels at defined time points for patients randomly assigned to the FCR arm. MRD detectable or not at 3 months (A); cutoff levels of 10⁻³, 10⁻², and 10⁻¹ at 3 months (B); MRD detectable or not at 12 months (C); cutoff levels of 10⁻³, 10⁻², and 10⁻¹ at 12 months (D); MRD detectable or not at 24 months (E); cutoff levels of 10⁻³, 10⁻², and 10⁻¹ at 24 months (F); MRD detectable or not at 36 months (G); and cutoff levels of 10⁻³, 10⁻², and 10⁻¹ at 36 months (H).

This Feature Is Available To Subscribers Only